ScreenerHero

GMAB Genmab A/S

CPH · DK · Healthcare · Biotechnology · genmab.com
2257.00DKK-2.42%Mkt Cap: 20.52B $P/E: 27.06

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with rel…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated - Common Stock
$127.85BUSDP/E 29.4
MRNA
Moderna, Inc. - Common Stock
$75.86BUSD
REGN
Regeneron Pharmaceuticals, Inc. - Common Stock
$75.69BUSDP/E 18.2
ARGX
argenx SE - American Depositary Shares
$57.51BUSDP/E 35.1
ARGX
ARGENX SE
$55.45BUSDP/E 35.2
RVMD
Revolution Medicines, Inc. - Common Stock
$44.29BUSD
UCB
UCB SA
$42.34BUSDP/E 18.1
ONC
BeOne Medicines Ltd. - American Depositary Shares
$40.51BUSDP/E 63.9
RPRX
Royalty Pharma plc - Class A Ordinary Shares
$33.03BUSDP/E 30.7
ALNY
Alnylam Pharmaceuticals, Inc. - Common Stock
$29.40BUSDP/E 38.3
ROIV
Roivant Sciences Ltd. - Common Shares
$25.80BUSD
BNTX
BioNTech SE - American Depositary Shares
$24.34BUSD
INSM
Insmed Incorporated - Common Stock
$24.27BUSD
INCY
Incyte Corporation - Common Stock
$23.37BUSDP/E 14.7
JAZZ
Jazz Pharmaceuticals plc - Ordinary Shares
$15.30BUSDP/E 16.1
ASND
Ascendis Pharma A/S - Ordinary Share
$14.99BUSDP/E 17.8
EXEL
Exelixis, Inc. - Common Stock
$14.47BUSDP/E 18.4
SMMT
Summit Therapeutics Inc. - Common Stock
$13.37BUSD
BBIO
BridgeBio Pharma, Inc. - Common Stock
$13.15BUSD
CORT
Corcept Therapeutics Incorporated - Common Stock
$12.56BUSDP/E 264.2

Key Statistics

Company
Market Cap20.52B USD
Enterprise Value20.66B USD
Revenue (TTM)601.69M USD
Gross Profit507.16M USD
Net Income (TTM)140.26M USD
Revenue/Share67.06 DKK
Last Price2257.00 DKK
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees3.1K
CountryDK
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)27.06
P/E (Forward)21.23
PEG4.48
EV/EBITDA103.02
EV/Revenue34.34
P/S34.94
P/B3.53
EPS (TTM)83.41
EPS (Forward)108.97
52W Range
1512.0087% of range2369.00
52W High2369.00 DKK
52W Low1512.00 DKK
Profitability
Gross Margin93.60%
Oper. Margin35.24%
EBITDA Margin33.33%
Profit Margin25.89%
ROE16.47%
ROA7.48%
Growth
Revenue Growth24.90%
Earnings Growth-9.40%
Cash Flow & Leverage
Operating CF172.74M USD
CapEx (TTM)8.01M USD
FCF Margin21.08%
FCF Yield0.62%
Net Debt548.09M USD
Net Debt/EBITDA2.73
Balance Sheet
Debt/Equity0.93
Current Ratio2.46
Quick Ratio2.44
Book Value/Sh656.06 DKK
Cash/Share25.29 DKK
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 DKK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)2453.79 DKK
Upside (mean)+8.7%
Target Range1400.00 DKK – 2930.00 DKK
1400.00+8.7% to mean2930.00
# Analysts15
Ownership
Shares Out.62.41M
Float58.96M
Insiders1.12%
Institutions42.45%
Technical
SMA 502098.32 (+7.6%)
SMA 2001897.63 (+18.9%)
Beta0.70
S&P 52W Chg13.94%
Avg Vol (30d)106.98K
Avg Vol (10d)129.67K
Technical Indicators
RSI (14)56.9
MACD58.0600
MACD Signal60.1012
MACD Hist.-2.0412
BB Upper2388.29 DKK
BB Middle2225.20 DKK
BB Lower2062.11 DKK
BB Width14.66%
ATR (14)53.60 DKK
Vol Ratio (20d)1.00x